Dysregulation of FGFR1 has been observed in several cancers, including lung cancer, breast cancer, renal cell carcinoma (RCC), and head and neck tumors, where its overexpression is often associated with poor prognosis [5–8]. Here, FGFR1 is linked to breast carcinoma.